Qualifications

• MBBS
• FRACP

Projects (1)

Publications (55)

2022 (3)

• The National COVID-19 Clinical Evidence Taskforce: pregnancy and perinatal guidelines.
  Homer CS, Roach V, Cusack L, Giles ML, Whitehead C, Burton W, Downton T, Gleeson G, Gordon A, Hose K, Hunt J, Kitschke J, McDonnell N, Middleton P, Oats JJ, Shand AW, Wilton K, Vogel J, Elliott J, McGloughlin S, McDonald SJ, White H, Cheyne S, Turner T; National COVID-19 Clinical Evidence Taskforce.
  Med J Aust. 2022 Oct; 217(Suppl 9):S14-S19
• The Australian living guidelines for the clinical care of people with COVID-19: What worked, what didn't and why, a mixed methods process evaluation.
  Turner T, Elliott J, Tendal B, Vogel JP, Norris S, Tate R, Green S; National COVID-19 Clinical Evidence Taskforce.
  PLoS One. 2022 Jan; 17(1):e0261479
• Awareness, Value and Use of the Australian living guidelines for the clinical care of people with COVID-19: An impact evaluation.
  Millard T, Elliott JH, Green S, Tendal B, Vogel JP, Norris S, Tate R, Turner T; National COVID-19 Clinical Evidence Taskforce.
  J Clin Epidemiol. 2022 Jan; 143:11-21

2021 (2)

• A New Method for Estimating the Incidence of Infectious Diseases.
  McManus H, Callander D, Asselin J, McMahon J, Hoy JF, Templeton DJ, Fairley CK, Donovan B, Pedrana AE, Keen P, Wilson DP, Elliott J, Kaldor J, Liaw ST, Petoumenos K, Holt M, Hellard ME, Grulich AE, Carr A, Stoové MA, Guy RJ
  Am J Epidemiol. 2021 Feb; 190(7):1386-1395
• Weekly updates of national living evidence-based guidelines: Methods for the Australian Living Guidelines for Care of People with COVID-19.
  Tendal B, Vogel JP, McDonald S, Norris S, Cumpston M, White H, Leder K, Navarro DF, Cheyne S, Chakraborty S, Murano M, Millard T, Callesen HE, Islam RM, Elliott J, Turner T; National COVID-19 Clinical Evidence Taskforce.
  J Clin Epidemiol. 2021 Jan; 131:11-21

2019 (1)

• Performance of a novel low-cost, instrument-free plasma separation device for HIV viral load quantification and determination of treatment failure in people living with HIV in Malaysia: a diagnostic accuracy study.
  Pham MD, Haile BA, Azwa I, Kamarulzaman A, Raman N, Saeidi A, Bador MK, Tan M, Zhu J, Yi F, Elliott JH, Garcia ML, Li F, Crowe SM, Luchters S, Anderson DA
  J Clin Microbiol. 2019 Jan; 57(4):e01683-18

2017 (2)

• Persistence of activated and adaptive-like NK cells in HIV+ individuals despite 2 Years of suppressive combination antiretroviral therapy.
  Hearps AC, Agius PA, Zhou J, Brunt S, Chachage M, Angelovich TA, Cameron PU, Giles M, Price P, Elliott J, Jaworowski A
  Front Immunol. 2017 Jun; 8:731
• No adverse safety or virological changes two years following vorinostat in HIV-infected individuals on antiretroviral therapy.
  Mota TM, Rasmussen TA, Rhodes A, Tennakoon S, Dantanarayana A, Wightman F, Hagenauer M, Roney J, Spelman T, Purcell DF, McMahon J, Hoy JF, Prince HM, Elliott JH, Lewin SR
  AIDS. 2017 May; 31(8):1137-1141

2016 (3)

• Polymorphisms in the CD14 and TLR4 genes independently predict CD4+ T-cell recovery in HIV-infected individuals on antiretroviral therapy.
  Yong YK, Shankar EM, Solomon A, Spelman T, Fairley CK, Elliott J, Hoy J, Cameron P, Kamarulzaman A, Lewin SR
  AIDS. 2016 Jun; 30(14):2159-2168
• The Positive Outlook Study: A Randomised Controlled Trial Evaluating Online Self-Management for HIV Positive Gay Men.
  Millard T, Agius PA, McDonald K, Slavin S, Girdler S, Elliott JH
  AIDS Behav. 2016 Feb; 20(9):1907-1918
• Chronic Disease Self-Management by People With HIV.
  McDonald K, Slavin S, Pitts MK, Elliott JH and the HealthMap Project Team
  Qual Health Res. 2016 Jan; 26(6):863-870

2015 (3)

• Modeling the Effects of Vorinostat In Vivo Reveals both Transient and Delayed HIV Transcriptional Activation and Minimal Killing of Latently Infected Cells.
  Ke R, Lewin SR, Elliott JH, Perelson AS
  PLoS Pathog. 2015 Oct; 11(10):e1005237
• An NK Cell Population Lacking FcRgamma Is Expanded in Chronically Infected HIV Patients.
  Zhou J, Amran FS, Kramski M, Angelovich TA, Elliott J, Hearps AC, Price P, Jaworowski A
  J Immunol. 2015 Apr; 194(10):4688-4697
• Experiences and expectations of participants completing an HIV cure focused clinical trial.
  McMahon JH, Elliott JH, Roney J, Hagenauer M, Lewin SR
  AIDS. 2015 Jan; 29(2):248-250

2014 (6)

• Informing the development of an online self-management program for men living with HIV: a needs assessment.
  MIllard T, McDonald K, Elliott J, Slavin S, Rowell S, Girdler S
  BMC Public Health. 2014 Nov; 14:1209
• Activation of HIV Transcription with Short-Course Vorinostat in HIV-Infected Patients on Suppressive Antiretroviral Therapy.
  Elliott JH, Wightman F, Solomon A, Ghneim K, Ahlers J, Cameron MJ, Smith MZ, Spelman T, McMahon J, Velayudham P, Brown G, Roney J, Watson J, Prince MH, Hoy JF, Chomont N, Fromentin R, Procopio FA, Zeidan J, Palmer S, Odevall L, Johnstone RW, Martin BP, Sinclair E, Deeks SG, Hazuda DJ, Cameron PU, Sékaly RP, Lewin SR
  PLoS Pathog. 2014 Oct; 10(10):e1004473
• The positive outlook study- a randomised controlled trial evaluating the effectiveness of an online self-management program targeting psychosocial issues for men living with HIV: a study protocol.
  Millard T, Elliott J, Slavin S, McDonald K, Rowell S, Girdler S
  BMC Public Health. 2014 Feb; 14:106
• Compartmentalization of innate immune responses in the central nervous system during cryptococcal meningitis/HIV coinfection.
  Naranbhai V, Chang CC, Durgiah R, Omarjee S, Lim A, Moosa MY, Elliot JH, Ndung'u T, Lewin SR, French MA, Carr WH
  AIDS. 2014 Jan; 28(5):657-666
• Targets for intervention to improve virological outcomes for patients receiving free antiretroviral therapy in Tamil Nadu, India.
  McMahon JH, Manoharan A, Wanke C, Mammen S, Jose H, Malini T, Kadavanu T, Jordan MR, Elliott JH, Lewin SR, Mathai D
  AIDS Care. 2014 Jan; 26(5):559-566
• Associations between surface markers on blood monocytes and carotid atherosclerosis in HIV-positive individuals.
  Westhorpe CL, Maisa A, Spelman T, Hoy JF, Dewar EM, Karapanagiotidis S, Hearps AC, Cheng WJ, Trevillyan J, Lewin SR, Sviridov D, Elliott JH, Jaworowski A, Dart AM, Crowe SM
  Immunol Cell Biol. 2014 Jan; 92(2):133-138

2013 (9)

• Towards an HIV cure: science and debate from the International AIDS Society 2013 symposium
  Purcell, DF, Elliott, JH, Ross, AL, Frater, J
  Retrovirology. 2013 Dec; 10:134
• Chemokine levels and chemokine receptor expression in blood and the CSF of HIV-infected patients with cryptococcal meningitis and C-IRIS.
  Chang CC, Omarjee S, Lim A, Spelman T, Gosnell BI, Carr WH, Elliott JH, Moosa MY, Ndung'u T, French MA, Lewin SR
  J Infect Dis. 2013 Aug; 208(10):1604-1612
• Impact of HIV-associated conditions on mortality in people commencing anti-retroviral therapy in resource limited settings.
  Marshall CS, Curtis AJ, Spelman T, O'Brien DP, Greig J, Shanks L, du Cros P, Casas EC, da Fonseca MS, Athan E, Elliott JH
  PLoS One. 2013 Jul; 8(7):e68445
• Cryptococcosis-IRIS is associated with lower Cryptococcus-specific IFN-gamma responses before antiretroviral therapy but not higher T-cell responses during therapy.
  Chang CC, Lim A, Omarjee S, Levitz SM, Gosnell BI, Spelman T, Elliott JH, Carr WH, Moosa MY, Ndung'u T, Lewin SR, French MA
  J Infect Dis. 2013 Jun; 208(6):898-906
• Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review.
  James H McMahon, Julian H Elliott, Silvia Bertagnolio, Rachel Kubiak, Michael R Jordan
  Bull World Health Organ. 2013 May; 91(5):377-385E
• Clinical and mycological predictors of cryptococcosis-associated Immune reconstitution inflammatory syndrome (C-IRIS).
  Chang CC, Dorasamy AA, Gosnell BI, Elliott JH, Spelman T, Omarjee S, Naranbhai V, Coovadia Y, Ndung'u T, Moosa MY, Lewin SR, French MA
  AIDS. 2013 Mar; 27(13):2089-2099
• Pharmacy and Self-Report Adherence Measures to Predict Virological Outcomes for Patients on Free Antiretroviral Therapy in Tamil Nadu, India.
  McMahon JH, Manoharan A, Wanke CA, Mammen S, Jose H, Malini T, Kadavanu T, Jordan MR, Elliott JH, Lewin SR, Mathai D
  AIDS Behav. 2013 Feb; 17(6):2253-2259
• Effects of physical tracing on estimates of loss to follow-up, mortality and retention in low and middle income country antiretroviral therapy programs: a systematic review.
  McMahon JH, Elliott JH, Hong SY, Bertagnolio S, Jordan MR
  PLoS One. 2013 Feb; 8(2):e56047
• Self-Management Education Programs for People Living with HIV/AIDS: A Systematic Review.
  Millard T, Elliott J, Girdler S
  AIDS Patient Care STDS. 2013 Feb; 27(2):103-113

2012 (3)

• Incidence of WHO Stage 3 and 4 Conditions following Initiation of Anti-Retroviral Therapy in Resource Limited Settings.
  Curtis AJ, Marshall CS, Spelman T, Greig J, Elliot JH, Shanks L, Du Cros P, Casas EC, Da Fonseca MS, O'Brien DP
  PLoS One. 2012 Dec; 7(12):e52019
• Short Communication: Plasma Levels of Vitamin D in HIV Patients Initiating Antiretroviral Therapy Do Not Predict Immune Restoration Disease Associated with Mycobacterium tuberculosis.
  Price P, Haddow LJ, Affandi J, Agarwal U, Easterbrook PJ, Elliott J, French M, Kumar M, Moosa MY, Oliver B, Singh S, Sola M, Saphonn V, Vun MC
  AIDS Res Hum Retroviruses. 2012 Oct; 28(10):1216-1219
• Tuberculosis after commencing antiretroviral therapy for HIV infection is associated with elevated CXCL9 and CXCL10 responses to Mycobacterium tuberculosis antigens.
  Oliver BG, Elliott JH, Price P, Phillips M, Cooper DA, French MA
  J Acquir Immune Defic Syndr. 2012 Jun; 61(3):287-292

2011 (8)

• Mycobacterial antibody levels and immune restoration disease in HIV patients treated in South East Asia.
  Sumatoh HR, Oliver BG, Kumar M, Elliott JH, Vonthanak S, Vun MC, Singh S, Agarwal U, Kumar A, Tan HY, Kamarulzaman A, Yunihastuti E, Saraswati H, Price P.
  Biomark Med. 2011 Dec; 5(6):847-853
• HIV and ageing: an overview of an emerging issue.
  Slavin S, Elliott J, Fairley C, French M, Hoy J, Law M, Lewin S
  Sex Health. 2011 Dec; 8(4):449-451
• Repeated assessments of food security predict CD4 change in the setting of antiretroviral therapy.
  McMahon JH, Wanke CA, Elliott JH, Skinner S, Tang AM
  J Acquir Immune Defic Syndr. 2011 Sep; 58(1):60-63
• Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients.
  Yong MK, Elliott JH, Woolley IJ, Hoy JF
  J Acquir Immune Defic Syndr. 2011 Jul; 57(3):205-210
• Drug-resistant tuberculosis in 9 high burden Asian countries. (Report)
  Majumdar S, Kong F, du Cros P, O’Brien D, Reeder J, Elliott J
  AusAID Health Resource Facility. Australian Government, Canberra. 2011 Jul
• Social meanings of adherence to antiretroviral therapy in Cambodia.
  Elliott J, Phlong P, Saphon V, Kaldor J, Mean C, Maher L
  Cult Health Sex. 2011 Jun; 13(6):685-697
• Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring.
  McMahon JH, Jordan MR, Kelley K, Bertagnolio S, Hong SY, Wanke CA, Lewin SR, Elliott JH
  Clin Infect Dis. 2011 Feb; 52(4):493-506
• Finding a cure for HIV: will it ever be achievable?
  Lewin SR, Evans VA, Elliott JH, Spire B, Chomont N
  J Int AIDS Soc. 2011 Jan; 14:4

2010 (6)

• Interferon-gamma and IL-5 production correlate directly in HIV patients co-infected with mycobacterium tuberculosis with or without immune restoration disease.
  Oliver BG, Elliott JH, Saphonn V, Vun MC, French MA, Price P
  AIDS Res Hum Retroviruses. 2010 Dec; 26(12):1287-1289
• Mediators of innate and adaptive immune responses differentially affect immune restoration disease associated with Mycobacterium tuberculosis in HIV patients beginning antiretroviral therapy.
  Oliver BG, Elliott JH, Price P, Phillips M, Saphonn V, Vun MC, Kaldor JM, Cooper DA, French MA
  J Infect Dis. 2010 Dec; 202(11):1728-1737
• Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.
  Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, Bohjanen PR, Sungkanuparph S, Easterbrook PJ, French MA, Boulware DR; International Network for the Study of HIV-associated IRIS (INSHI).
  Lancet Infect Dis. 2010 Nov; 10(11):791-802
• Preliminary assessment of Treponema pallidum-specific IgM antibody detection and a new rapid point-of-care assay for the diagnosis of syphilis in human immunodeficiency virus-1-infected patients.
  Rotty J, Anderson D, Garcia M, Diaz J, Van de Waarsenburg S, Howard T, Dennison A, Lewin SR, Elliott JH, Hoy J
  Int J STD AIDS. 2010 Nov; 21(11):758-764
• Biological determinants of immune reconstitution in HIV-infected patients receiving antiretroviral therapy: the role of interleukin 7 and interleukin 7 receptor alpha and microbial translocation.
  Rajasuriar R, Booth D, Solomon A, Chua K, Spelman T, Gouillou M, Schlub TE, Davenport M, Crowe S, Elliott J, Hoy J, Fairley C, Stewart G, Cameron P, Lewin SR
  J Infect Dis. 2010 Oct; 202(8):1254-1264
• Second line antiretroviral therapy for treatment of HIV in Asia
  Elliott JH
  Asian Biomedicine. 2010 Jan; 4:673-677

2009 (3)

• Immunopathogenesis and diagnosis of tuberculosis and tuberculosis-associated immune reconstitution inflammatory syndrome during early antiretroviral therapy.
  Elliott JH, Vohith K, Saramony S, Savuth C, Dara C, Sarim C, Huffam S, Oelrichs R, Sophea P, Saphonn V, Kaldor J, Cooper DA, Vun MC, French MA
  J Infect Dis. 2009 Dec; 200(11):1736-1745
• Immune restoration diseases reflect diverse immunopathological mechanisms.
  Price P, Murdoch DM, Agarwal U, Lewin SR, Elliott JH, French MA
  Clin Microbiol Rev. 2009 Oct; 22(4):651-663
• Long term management of people with HIV.
  Denholm JT, Yong MK, Elliott JH
  Aust Fam Physician. 2009 Aug; 38(8):574-577

2008 (3)

• Protease inhibitor therapy in resource-limited settings.
  Elliott JH, Pujari S
  Curr Opin HIV AIDS. 2008 Nov; 3(6):612-619
• Sustainability science: an integrated approach for health-programme planning.
  Gruen RL, Elliott JH, Nolan ML, Lawton PD, Parkhill A, McLaren CJ, Lavis JN
  Lancet. 2008 Nov; 372(9649):1579-1589
• Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
  Elliott JH, Lynen L, Calmy A, De Luca A, Shafer RW, Zolfo M, Clotet B, Huffam S, Boucher CAB, Cooper DA, Schapiro JM
  AIDS. 2008 Oct; 22(16):2053-2067

2007 (1)

• Use of evidence in WHO recommendations.
  Elliott JH, Gruen RL
  Lancet. 2007 Sep; 370(9590):826; author reply 826-826; author reply 827

2004 (1)

• The molecular epidemiology of HIV type 1 among Vietnamese Australian injecting drug users in Melbourne, Australia.
  Ryan CE, Elliott JH, Middleton T, Mijch AM, Street AC, Hellard M, Crofts N, Crowe SM, Oelrichs RB
  AIDS Res Hum Retroviruses. 2004 Dec; 20(12):1364-1367

2003 (1)

• HIV, ethnicity and travel: HIV infection in Vietnamese Australians associated with injecting drug use.
  Elliott JH, Mijch AM, Street AC, Crofts N
  J Clin Virol. 2003 Feb; 26(2):133-142

News Articles (3)

2017 (1)

• Prestigious award for Burnet Associate

2012 (2)

• Burnet NHMRC grants announcement
• Burnet's scientists join world leaders at AIDS 2012 Conference